Gossamer Bio Profit Margin

The latest profit margin for GOSS is -235.0% as of June 2026. That compares with -344.81% in the prior-year period — up 31.8% year over year. That is below the Healthcare sector average of 21.34%. Investors often review this figure alongside Gossamer Bio's historical trend and sector peers before judging valuation or financial health.

Over the past year, GOSS's profit margin moved from -344.81% to -235.0% — a 31.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Gossamer Bio's valuation or profitability profile.

Against Healthcare companies, GOSS currently prints -235.0% for profit margin, while the sector average sits near 21.34%. That is roughly 1201.5% below the sector mean. Large gaps often invite a closer look at Gossamer Bio's growth, margins, and balance sheet.

Profit Margin shows how effectively Gossamer Bio converts resources into returns. At -235.0%, GOSS may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -344.81% in the prior-year period — up 31.8% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting GOSS's profit margin (-235.0%), review year-over-year change from -344.81%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.